Key facts
- This page summarizes Wang Theodore T.'s Form 4 filing for Bellerophon Therapeutics, Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2023, 16:10.
Wang Theodore T. - 07 Jun 2023 Form 4 Insider Report for Bellerophon Therapeutics, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 07 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2023, 16:10:38 UTC
- Prior SEC filing
- 15 May 2023
- Next SEC filing
- 30 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Theodore T. Wang
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Wang Theodore T. filed Form 4 for Bellerophon Therapeutics, Inc. on 09 Jun 2023.
Change
- Previous filing in this sequence was filed on 15 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
BLPH
transaction
Derivative
Stock Options (Right to Buy)
Award
- Transaction value
- $0
- Shares
- -14,607
- Change %
- -50%
- Price
- $0.000000
- Shares after
- 14,607
- Date
- 07 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,607
- Exercise price
- $0.8264
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option was approved by the Compensation Committee of the Board of Directors of Bellerophon Therapeutics, Inc., on February 10, 2023, contingent upon stockholder approval of an amendment to the Company's 2015 Equity Incentive Plan under which the options were granted, which was approved by stockholders on June 7, 2023.
Footnote F2
This option vests in full on June 7, 2024.